Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).
Lijuan ZengJamie PerinAlden L GrossDavid ShadeKrista L LanctôtAlan J LernerJacobo E MintzerOlga Brawman-MintzerPrasad R PadalaChristopher H van DyckAnton P PorsteinssonSuzanne CraftAllan LeveyNathan HerrmannPaul B RosenbergPublished in: International journal of geriatric psychiatry (2024)
MPH use in AD patients for treating apathy is relatively safe, particularly notable given the many medical comorbidities in this population. There was a statistically significant but modest weight loss associated with MPH use, and clinicians are thus advised to monitor weight during MPH treatment.
Keyphrases
- weight loss
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- healthcare
- attention deficit hyperactivity disorder
- body mass index
- peritoneal dialysis
- clinical trial
- prognostic factors
- physical activity
- study protocol
- randomized controlled trial
- cognitive decline
- weight gain
- type diabetes
- autism spectrum disorder
- skeletal muscle
- gastric bypass
- patient reported outcomes
- molecular docking
- adipose tissue
- mild cognitive impairment